title: Neonatal screening for metabolic and endocrine disorders.
abstract: BACKGROUND
  Neonatal screening for treatable endocrinopathies and inborn errors of metabolism is an important preventive measure. Advances in the diagnosis and treatment of these diseases have made it necessary to expand the screening program.
  
  
  METHODS
  This article is based on a selective literature review and our clinical experience.
  
  
  RESULTS
  In 2005, neonatal screening in Germany was expanded from 3 to 14 diseases, as mandated by the responsible governmental authority (the Gemeinsamer Bundesausschuss, i.e., Joint Federal Committee). From 2005 to 2008, screening revealed diseases requiring treatment in 1932 out of a total of 2,758,633 newborns (prevalence, 1 in 1428). The expansion of the screening program resulted in a 57% increase in the overall number of cases detected and a 92% increase for metabolic diseases alone.
  
  
  CONCLUSIONS
  The German neonatal screening program for treatable endocrinopathies and inborn errors of metabolism is a complex and integrated preventive measure that has become markedly more effective as a result of its expansion in 2005.
authors.affiliation: Klinik für Kinder- und Jugendmedizin – Allgemeine Pädiatrie – der Westfä -lischen Wilhelms-Universität Münster. harms@uni-muenster.de
authors.forename: Erik
authors.initials: E
authors.lastname: Harms
authors.forename: Bernhard
authors.initials: B
authors.lastname: Olgemöller
mesh_terms: D004700:Endocrine System Diseases / Q000175:diagnosis* / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008659:Metabolic Diseases / Q000175:diagnosis* / Q000517:prevention & control*; D015997:Neonatal Screening / Q000379:methods* / Q000639:trends*